Melanoma Milestone: FDA Approved Treatment Developed By This Company

Lyell Immunopharma Achieves FDA Orphan Drug Designation for Groundbreaking Melanoma Treatment.

Lyell Immunopharma, a trailblazing biotechnology company, has recently achieved a significant milestone in its mission to revolutionize cancer therapy. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its pioneering cell therapy product, an autologous, epigenetically modified solution that uses expanded tumor-infiltrati…